Lasa Supergenerics logs 362% sequential growth in PAT in Q4FY22; stock skyrockets ~15%

11 Apr 2022 , 04:36 PM

Lasa Supergenerics Limited, a vertically integrated group spanning the entire animal and human healthcare value chain has announced its financial results for the fourth quarter and Financial Year ended March 31, 2022.

Lasa’s counter zoomed as much as 15% in today’s trade following its robust growth announcement during the current fiscal year.

The company reported that its revenues from operations stood at Rs51.21 crore in Q4FY22 as compared to Rs15.74 crore in Q3FY22, up by 225% sequentially. Its EBITDA for Q4FY22 was Rs10.93 crore as against a negative EBITDA of Rs1.18 crore in Q3FY22. EBITDA margin was at 21.35% in the current quarter.

Its PAT during the quarter stood at Rs12.35 crore as compared to a loss of Rs4.71 crore in Q3FY22.

The company reported that its total income for the FY22 ended March 31, 2022, at Rs137.13 crore. It reported Earnings Before Interest, Tax, Depreciation, and Amortization (EBITDA) of Rs15.69 crore in FY22.

The Company reported a loss of Rs5.31 crore for FY22 which was mainly due to the absorption of exceptional items during the year.

Lasa’s stock was trading at Rs62.80, up by 14.91% against its previous close of Rs54.65 on NSE. It touched intraday high and low of Rs65.50 and Rs55.60 respectively.